ClinicalTrials.gg
WithdrawnNCT01590225Updated Jan 29, 2021

Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)

A Phase 3 interventional study of Boceprevir and Peginterferon alpha-2b in Chronic Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Withdrawn. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-01-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
36th of 39
0 · median 99
Started
2013
with 2 others
Phase 3
22 of 40
none open now
Registered
35th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 36th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2013, is one of 22 in phase 3, and was the 35th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

This is a three-part (Part A, Part B, and Part C), open-label, multicenter study of boceprevir in pediatric participants with chronic hepatitis C (CHC) genotype 1 (GT1). In Part A and Part B, efficacy and safety will be evaluated in participants with CHC GT1 who are non-cirrhotic, treatment naïves (Part A) or who are non-cirrhotic, treatment failures to (peg)interferon/ribavirin or who are cirrhotics (whether treatment naïve or treatment failure) (Part B). Part C is long-term follow up and no study treatment will be administered during this period, but participants who do not achieve viral clearance will be allowed to receive other treatments for CHC.

03

Conditions studied

  • Chronic Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CHC GT1 infection for at least 6 months with with ≥10,000 IU/mL.
  • Treatment naive, non-cirrhotic participants will be eligible for inclusion in Study Part A
  • Non-cirrhotic subjects who failed previous (peg)interferon/ribavirin treatment for CHC and cirrhotics, whether treatment naive or treatment failure, will be eligible for inclusion in Study Part B
  • To participate in Study Part C, participants must have completed the required post-treatment follow-up in Study Part A or Part B
  • Weight ≥ 10 kg to ≤ 125 kg
  • Body surface area (BSA) ≥0.46 m\^2 and ≤2.5 m\^2
  • Previous liver with histology consistent with chronic hepatitis C and no other etiology within 2 years of the screening visit
  • Participants with bridging fibrosis or cirrhosis must have an ultrasound within 6 months of the screening visit or between the screening visit and Day 1 with no findings suspicious for hepatocellular carcinoma
  • Participant must be able to adhere to dose and visit schedules

Exclusion criteria

Exclusion Criteria:

  • Known co-infection with the the (HIV) or virus (HBsAg positive)
  • For Study Part A, participant received any prior treatment, including herbal remedies, with known hepatotoxicity
  • For Study Part B, participant received treatment with ribavirin within 90 days or any interferon alpha within 30 days prior to screening
  • For Study Part B, participant received previous treatment with a hepatitis C virus protease inhibitor (excepting participants in study P07614, Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1)
  • For Study Part B, participant required discontinuation of previous (peg)interferon/ribavirin therapy for an adverse event considered by the investigator to be related to (peg)interferon and/or ribavirin
  • For Study Part B, participant is currently taking any antiviral/immunomodulatory treatment for hepatitis C
  • Participant has taken any drugs, except boceprevir
  • Participant has received any of the following medication(s) within 2 weeks prior to the Day 1 visit: midazolam, pimozide, amiodarone, flecainide,

propafenone, quinidine, and ergot derivatives (dihydroergotamine, ergonovine,

ergotamine, methylergonovine)

  • Participation in any other clinical trial within 30 days of enrollment or

intent to participate in another clinical trial during participation in the current study

  • Evidence of decompensated liver disease
  • score >6 (class B and C)
  • History of diabetes or hypertension or was born prior to 32 weeks

of gestation and has ocular examination findings

  • Pre-existing clinically significant psychiatric condition(s)
  • Clinical diagnosis of substance abuse
  • Any pre-existing medical condition that could interfere with participation in and completion of the study
  • Evidence of active or suspected
  • Females who are pregnant, nursing, or intend to become pregnant during

the study period

  • Allergy or sensitivity to the investigational products or
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part A: boceprevir + peginterferon alpha-2b + ribavirin

    Drug: Boceprevir · Drug: Peginterferon alpha-2b · Drug: Ribavirin

  • Experimental
    Part B: boceprevir + peginterferon alpha-2b + ribavirin

    Drug: Boceprevir · Drug: Peginterferon alfa-2b · Drug: Ribavirin

Interventions

  • Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.

    Also known as: Victrelis®, SCH 503034

  • Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 24 weeks.

    Also known as: Pegintron®, Sylatron®

  • The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 24 weeks.

    Also known as: Copegus®, Rebetol®, RibaTab®, Ribasphere®

  • Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.

  • Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 48 weeks.

    Also known as: Pegintron®, Sylatron®

  • Drug: Ribavirin The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 48 weeks.

    Also known as: Copegus®, Rebetol®, RibaTab®, Ribasphere®

06

What researchers measure

Primary outcomes

  1. Participants Achieving Sustained Viral Response (SVR) at Follow-Up Week 24 in Study Part A

    Time frame: Follow-Up Week 24

  2. Participants Achieving SVR at Follow-Up Week 24 in Study Part B

    Time frame: Follow-Up Week 24

  3. Time to Viral Relapse in Study Part C

    Time frame: Follow-Up Week 24 to 5 Years

Secondary outcomes

  1. Proportion of Participants With Alanine Aminotransferase (ALT) Normalization in Study Part A

    Time frame: Week 2, Week 4, Week 8, Week 12

  2. Participants With Early Virologic Response in Study Part A

    Time frame: Week 2, Week 4, Week 8, Week 12

  3. Proportion of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA) in Study Part A

    Time frame: Week 12, End of Treatment, Follow-Up Week 24

  4. Proportion of Participants With Undetectable HCV-RNA Who Also Achieved SVR in Study Part A

    Time frame: Follow-Up Week 12

  5. Proportion of Participants With Alanine Aminotransferase (ALT) Normalization in Study Part B

    Time frame: Week 2, Week 4, Week 8, Week 12

  6. Proportion of Participants With Undetectable HCV-RNA in Study Part B

    Time frame: Week 24, End of Treatment, Follow-Up Week 12

  7. Proportion of Participants With Undetectable HCV-RNA Who Also Achieved SVR in Study Part B

    Time frame: Follow-Up Week 12

  8. Number of Participants Experiencing Treatment-Emergent Adverse Events (AEs) in Study Part A

    Time frame: Week 1 to Follow-Up Visit 24

  9. Number of Participants Experiencing Treatment-Emergent Treatment-Related AEs in Study Part A

    Time frame: Week 1 to Follow-Up Week 24

  10. Number of Participants Experiencing Serious AEs (SAEs) in Study Part A

    Time frame: Week 1 to Follow-Up Week 24

  11. Participants Discontinuing Treatment Due to AEs in Study Part A

    Time frame: Week 1 to Follow-Up Week 24

  12. Change from Baseline in Participant Laboratory Values in Study Part A

    Time frame: Baseline to Follow-Up Week 24

  13. Change From Baseline in Participant Vital Signs in Study Part A

    Time frame: Baseline to Follow-Up Week 24

  14. Number of Participants Experiencing AEs in Study Part B

    Time frame: Week 1 to Follow-Up Week 24

  15. Number of Participants Experiencing SAEs in Study Part B

    Time frame: Week 1 to Follow-Up Week 24

  16. Change from Baseline in Participant Laboratory Values in Study Part B

    Time frame: Week 1 to Follow-Up Week 24

  17. Change From Baseline in Participant Vital Signs in Study Part B

    Time frame: Week 1 to Follow-Up Week 24

  18. Number of Participants Discontinuing From Study Treatment Due to AEs in Study Part B

    Time frame: Week 1 to Follow-Up Week 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2013 (actual). Primary completion is estimated for Aug 2021, 102 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2012
First posted
May 2, 2012
StartActual
Jan 28, 2013
Primary completionEst.
Aug 18, 2021
CompletionEst.
Aug 18, 2021
Last update
Jan 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01590225
Responsible party
Sponsor
First posted
May 2, 2012
Start date
Jan 28, 2013
Primary completion
Aug 18, 2021 (estimated)
Completion
Aug 18, 2021 (estimated)
Last update
Jan 29, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion